FDA panel backs J&J’s potential depression blockbusterA panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal Share XFDA panel backs J&J’s potential depression blockbusterhttps://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
NICE backs digital CBT for youngsters with depressionNICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and Share XNICE backs digital CBT for youngsters with depressionhttps://pharmaphorum.com/news/nice-backs-digital-cbt-for-youngsters-with-depression/
Mental health services falling behind rest of NHS – reportMental health services in the UK are falling behind physical health services because of outdated commissioning services in Share XMental health services falling behind rest of NHS – reporthttps://pharmaphorum.com/news/mental-health-services-falling-behind-rest-of-nhs-report/
Digital health round-up: Otsuka doubles down on digital mental health treatmentOtsuka seems to think it’s onto something by using digital tech to aid treatment of mental health disorders: Share XDigital health round-up: Otsuka doubles down on digital mental health treatmenthttps://pharmaphorum.com/views-analysis-digital/digital-health-round-up-otsuka-doubles-down-on-digital-mental-health-treatment/
Otsuka funds prescription therapy app for depressionOtsuka is once again betting on digital as a new avenue for depression treatment by collaborating with Click Share XOtsuka funds prescription therapy app for depressionhttps://pharmaphorum.com/news/otsuka-funds-app-depression/
Healios begins trials of mental health app for schoolchildrenDigital health firm Healios is beginning clinical trials of ThinkNinja, an app designed to help children with mental Share XHealios begins trials of mental health app for schoolchildrenhttps://pharmaphorum.com/news/healios-begins-trials-of-mental-health-app-for-schoolchildren/
Magic mushroom drug could be depression breakthrough, says FDAThe liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new Share XMagic mushroom drug could be depression breakthrough, says FDAhttps://pharmaphorum.com/news/magic-mushroom-drug-could-be-depression-breakthrough-says-fda/
J&J preps for FDA panel grilling over depression drugJohnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling Share XJ&J preps for FDA panel grilling over depression drughttps://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/
EU regulators review Janssen’s esketamine nasal spray antidepressantAn application for Janssen’s investigative nasal ketamine-based antidepressant is under review in Europe. Janssen, which is Johnson & Share XEU regulators review Janssen’s esketamine nasal spray antidepressanthttps://pharmaphorum.com/news/eu-regulators-review-janssens-esketamine-nasal-spray-antidepressant/
